Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1

Conditions

Ovarian Neoplasms 4Endometrial Neoplasms 3Uterine Cervical Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Prostatic Neoplasms 1Pancreatic Neoplasms 1Neoplasms by Site 1Neoplasms 1Hereditary Sensory and Autonomic Neuropathies 1Head and Neck Neoplasms 1Endometrial Stromal Tumors 1Endometrial Hyperplasia 1Breast Neoplasms 1Breast Diseases 1

Interventions

Megestrol Acetate 7Medroxyprogesterone Acetate 4Progestins 3Metformin 3Tirzepatide 2Progesterone 2Letrozole 2Hysteroscopy 2Blood Specimen Collection 2Biopsy 2Atorvastatin 2semaglutide 1ricin A-GnRH conjugate 1exemestane 1estradiol, norethindrone drug combination 1Tamoxifen 1Surveys and Questionnaires 1Sampling Studies 1Rosuvastatin Calcium 1Restraint, Physical 1Resistance Training 1Pterocarpus marsupium 1Pharmacogenomic Variants 1Observation 1Nutrition Assessment 1Magnetic Resonance Spectroscopy 1Levonorgestrel 1LHRH, Ac-Nal(1)-Cpa(2)-Trp(3)-Arg(6)-Ala(10)- 1Intrauterine Devices 1Immunohistochemistry 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Endometrial Hyperplasia × exemestane × Gynecologic × Clear all
NCT03300557 2025-08-29

Exemestane in Treating Patients With Complex Atypical Hyperplasia of the Endometrium/Endometrial Intraepithelial Neoplasia or Low Grade Endometrial Cancer

National Cancer Institute (NCI)

Phase 2 Completed
40 enrolled 13 charts
Gynecologic

Endometrial Hyperplasia, Endometrial Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡